drugset / Trial / NCT06106295
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
Timeline
- Start
- 2023-12-19
- Primary completion
- 2028-01-31
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metyrapone | Small molecule | 250 mg | Oral |
| Subject | Metyrapone | Small molecule | 1000 mg | Oral |